NATCO launches fixed dose combination of Sofosbuvir-Daclatasvir drug for Hepatitis C treatment in INDIA

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announced today that it is the first company in India to launch under its brand Hepcinat Plus, the generic fixed dose combination of Sofosbuvir 400 mg and Daclatasvir 60mg Tablet, for the treatment of patients with chronic hepatitis C virus (HCV) infection.

Natco has launched Hepcinat Plus at an MRP of INR 17,500/-, for a bottle of 28 tablets.

Shares of NATCO PHARMA LTD. was last trading in BSE at Rs.791.65 as compared to the previous close of Rs. 794.15. The total number of shares traded during the day was 10411 in over 433 trades.

The stock hit an intraday high of Rs. 809.1 and intraday low of 784. The net turnover during the day was Rs. 8304680.

Source : Equity Bulls

Keywords